Cowen And Company, LLC Adicet Bio, Inc. Transaction History

Cowen And Company, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$1.21 - $2.4 $71,202 - $141,228	-58,845 Reduced 6.84%	801,298 $969,000
Q1 2024 May 03, 2024	SELL	$1.76 - $3.45 $3.27 Million - $6.4 Million	-1,855,135 Reduced 68.32%	860,143 $2.02 Million
Q4 2023 Feb 12, 2024	BUY	$1.11 - $1.89 $3.01 Million - $5.13 Million	2,715,278 New	2,715,278 $5.13 Million
Q3 2023 Nov 09, 2023	SELL	$1.37 - $3.4 $163,832 - $406,592	-119,586 Reduced 4.22%	2,715,278 $3.72 Million
Q2 2023 Aug 07, 2023	SELL	$2.13 - $7.13 $657,624 - $2.2 Million	-308,744 Reduced 9.82%	2,834,864 $6.89 Million
Q4 2022 Feb 09, 2023	BUY	$7.72 - $21.27 $5.41 Million - $14.9 Million	700,362 Added 28.67%	3,143,608 $28.1 Million
Q3 2022 Nov 14, 2022	SELL	$13.43 - $18.74 $7,171 - $10,007	-534 Reduced 0.02%	2,443,246 $34.7 Million
Q2 2022 Aug 05, 2022	BUY	$10.26 - $20.81 $9.68 Million - $19.6 Million	943,725 Added 62.91%	2,443,780 $35.7 Million
Q1 2022 May 16, 2022	BUY	$11.53 - $19.97 $17.3 Million - $30 Million	1,500,055 New	1,500,055 $30 Million

59.2M

4.2K

6.7K

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $39.6M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.